A detailed history of Financial Partners Group, Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Financial Partners Group, Inc holds 2,043 shares of ABBV stock, worth $478,062. This represents 0.06% of its overall portfolio holdings.

Number of Shares
2,043
Previous 1,484 37.67%
Holding current value
$478,062
Previous $275,000 72.0%
% of portfolio
0.06%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 17, 2025

BUY
$184.85 - $231.54 $103,331 - $129,430
559 Added 37.67%
2,043 $473,000
Q2 2025

Jul 15, 2025

BUY
$170.16 - $206.27 $1,701 - $2,062
10 Added 0.68%
1,484 $275,000
Q1 2025

May 06, 2025

SELL
$169.2 - $216.66 $114,717 - $146,895
-678 Reduced 31.51%
1,474 $308,000
Q4 2024

Jan 24, 2025

SELL
$164.99 - $203.87 $6,104 - $7,543
-37 Reduced 1.69%
2,152 $382,000
Q3 2024

Oct 30, 2024

BUY
$163.84 - $199.33 $1,310 - $1,594
8 Added 0.37%
2,189 $432,000
Q2 2024

Jul 19, 2024

SELL
$154.79 - $180.76 $77,240 - $90,199
-499 Reduced 18.62%
2,181 $374,000
Q1 2024

May 07, 2024

BUY
$159.82 - $182.1 $162,856 - $185,559
1,019 Added 61.35%
2,680 $488,000
Q4 2023

Feb 09, 2024

SELL
$137.6 - $154.97 $7,155 - $8,058
-52 Reduced 3.04%
1,661 $257,000
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $37,138 - $42,992
278 Added 19.37%
1,713 $255,000
Q2 2023

Aug 08, 2023

SELL
$132.51 - $164.9 $147,881 - $184,028
-1,116 Reduced 43.75%
1,435 $193,000
Q1 2023

May 12, 2023

BUY
$144.61 - $166.54 $30,368 - $34,973
210 Added 8.97%
2,551 $406,000
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $323,783 - $388,301
2,341 New
2,341 $378,000
Q2 2022

Aug 12, 2022

BUY
$137.62 - $174.96 $825 - $1,049
6 Added 0.44%
1,356 $208,000
Q1 2022

Apr 29, 2022

BUY
$131.98 - $163.75 $178,173 - $221,062
1,350 New
1,350 $219,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Financial Partners Group, Inc Portfolio

Follow Financial Partners Group, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Partners Group, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Financial Partners Group, Inc with notifications on news.